| | 3116-76-5 Basic information More.. |
| Product Name: | Dicloxacillin | | Synonyms: | )-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3///;4-thia-1-azabicyclo(3.2.0)heptane-2-carboxyl///;4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylicacid,6-(((3-(2,6-dichlorophenyl;6-(3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanicacid[qr;6-dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-6-(3-(;brl1702;6-[3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;R 13423 | | CAS: | 3116-76-5 | | MF: | C19H17Cl2N3O5S | | MW: | 470.33 | | EINECS: | 221-488-3 | | Mol File: | 3116-76-5.mol |  |
Use
Oral absorption: c. 50%
Cmax , 250 mg oral: 9 mg/L after 1 h
500 mg intramuscular: 14–16 mg/L after 0.5–1 h
Plasma half-life: 0.5 h
Plasma protein binding: 95–97%
Absorption
Absorption in the very young is poor and unpredictable.
Metabolism and excretion
Dicloxacillin is partly metabolized in the liver and about
10% of the circulating drug is in the form of metabolites.
Some 50–70% of a dose is excreted in the urine, about
20% as metabolites. It is eliminated both in the glomerular
filtrate and by tubular secretion, and plasma concentrations
are raised by probenecid. Parent drug and increased
proportions of metabolites accumulate in renal failure.
Elimination is increased through enhanced tubular secretion
in patients with cystic fibrosis.
- Dicloxacillin
-
- US $1.00 / KG
- 2024-08-11
- CAS:3116-76-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20T
- Dicloxacillin
-
- US $1.00 / KG
- 2020-02-01
- CAS:3116-76-5
- Min. Order: 1KG
- Purity: Min98% HPLC
- Supply Ability: G/KG/TON
|
|
3116-76-5
Recommend Suppliers |
|